How many insider trades does FilingIQ track for MBRX?

FilingIQ tracks 127 Form 4 insider transactions for MBRX (Moleculin Biotech, Inc.), covering filings from Aug 19, 2016 onwards. 18 of those were filed in the last 90 days.

Are MBRX insiders net buyers or net sellers?

Across the full Form 4 history for MBRX, 11 transactions (9%) were open-market purchases and 2 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MBRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MBRX in?

Moleculin Biotech, Inc. (MBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.11M.

MBRX insider trading

NasdaqCM Healthcare

Moleculin Biotech, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

127

Last 90 days

Buys / sells

9% / 2%

Market cap

$7.11M

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Company website: moleculin.com

MBRX insider activity at a glance

FilingIQ has scored 127 insider transactions for MBRX since Aug 19, 2016. The most recent filing in our index is dated Jun 22, 2026.

Across the full history, 11 open-market purchases and 2 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MBRX insider trades is 70.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MBRX trades on FilingIQ Raw filings on SEC EDGAR

Latest MBRX Form 4 filings

KLEMP WALTER V CEO and President

P Jun 23, 2025

Foster Jonathan P. Chief Financial Officer

P Jun 23, 2025

KLEMP WALTER V CEO and President

P Dec 26, 2023

Foster Jonathan P. Chief Financial Officer

P Dec 26, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,190

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

NTRA 133

Natera, Inc.

Frequently asked

How many insider trades does FilingIQ track for MBRX?: FilingIQ tracks 127 Form 4 insider transactions for MBRX (Moleculin Biotech, Inc.), covering filings from Aug 19, 2016 onwards. 18 of those were filed in the last 90 days.
Are MBRX insiders net buyers or net sellers?: Across the full Form 4 history for MBRX, 11 transactions (9%) were open-market purchases and 2 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MBRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MBRX in?: Moleculin Biotech, Inc. (MBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.11M.

Methodology & sources

Every MBRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.